News

Summit Therapeutics: AstraZeneca Partnership Could Be A Game-Changer, But Clinical Risks Remain
Summit Therapeutics nears a $15B AstraZeneca deal for ivonescimab, targeting a $90B market. See more on the potential and ...
The Pharma Letter26m
AstraZeneca in talks with Summit for over $15 billion license deal
UK pharma major AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal ...